A research study demonstrated that the use of the c-MET inhibitor tivantinib resulted in an increase in PD-L1 expression in NSCLC cell lines, leading to evasion of T-cell-mediated killing by cancer cells. Here, MET is linked to non-small cell lung carcinoma.